Epigral (EPIGRAL) Resumen de Acciones
Epigral Limited fabrica y vende cloro-álcali y derivados relacionados en India y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 2/6 |
| Salud financiera | 6/6 |
| Dividendos | 3/6 |
Recompensas
Análisis de riesgos
EPIGRAL Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Epigral Limited
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | ₹1,126.00 |
| Máximo en las últimas 52 semanas | ₹1,850.00 |
| Mínimo de 52 semanas | ₹807.00 |
| Beta | 0.19 |
| Cambio en 1 mes | -3.16% |
| Variación en 3 meses | -9.26% |
| Cambio de 1 año | -38.98% |
| Variación en 3 años | 27.21% |
| Variación en 5 años | 106.80% |
| Variación desde la OPV | 177.03% |
Noticias y actualizaciones recientes
Nueva narrativa • Aug 04
Epoxy Expansion Risks And Capital Strain Will Shape A Tougher Yet Ultimately Constructive Outlook
Catalysts About Epigral Epigral is an integrated chemical producer with a portfolio spanning chlor alkali, epichlorohydrin, CPVC, chloromethanes, chlorotoluenes, hydrogen peroxide and planned epoxy resins and specialty intermediates. What are the underlying business or industry changes driving this perspective?
Actualización de narrativa • Jul 21
EPIGRAL: New Subsidiary And Forthcoming Results Will Support Bullish View
Analysts have revised their fair value estimate for Epigral to ₹1,690 from ₹2,000, citing updated assumptions for revenue growth, profit margins, and future P/E expectations in their models. What's in the News for Epigral Epigral has incorporated a wholly owned subsidiary, Epigral Advanced Materials Limited, with the objective of manufacturing chemicals.
Nueva narrativa • Jul 21
Upcoming Specialty Expansion And Higher Chlorine Integration Will Strengthen Long Term Earnings Potential
Catalysts About Epigral Epigral is an Indian chemical producer with an integrated chlor alkali, derivatives and specialty chemicals portfolio. What are the underlying business or industry changes driving this perspective?Recent updates
Nueva narrativa • Aug 04
Epoxy Expansion Risks And Capital Strain Will Shape A Tougher Yet Ultimately Constructive Outlook
Catalysts About Epigral Epigral is an integrated chemical producer with a portfolio spanning chlor alkali, epichlorohydrin, CPVC, chloromethanes, chlorotoluenes, hydrogen peroxide and planned epoxy resins and specialty intermediates. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Jul 21
EPIGRAL: New Subsidiary And Forthcoming Results Will Support Bullish View
Analysts have revised their fair value estimate for Epigral to ₹1,690 from ₹2,000, citing updated assumptions for revenue growth, profit margins, and future P/E expectations in their models. What's in the News for Epigral Epigral has incorporated a wholly owned subsidiary, Epigral Advanced Materials Limited, with the objective of manufacturing chemicals.Nueva narrativa • Jul 21
Upcoming Specialty Expansion And Higher Chlorine Integration Will Strengthen Long Term Earnings Potential
Catalysts About Epigral Epigral is an Indian chemical producer with an integrated chlor alkali, derivatives and specialty chemicals portfolio. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Jun 07
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts have kept Epigral's fair value estimate steady at ₹2,000. They point to broadly unchanged assumptions on discount rate, revenue growth, profit margin and future P/E as the basis for maintaining their price target view.Actualización de narrativa • May 24
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts are keeping the fair value estimate for Epigral steady at ₹2,000, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers behind the updated price target framework. What's in the News Board meeting scheduled for May 2, 2026, to review audited standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2026, and to consider the statutory auditors' report (company filing).Artículo de análisis • May 08
Epigral Limited's (NSE:EPIGRAL) Sole Analyst Just Made A Substantial Upgrade To Their Forecasts
Celebrations may be in order for Epigral Limited ( NSE:EPIGRAL ) shareholders, with the covering analyst delivering a...Actualización de narrativa • Apr 21
EPIGRAL: Steady ₹2,000 View Ahead Of 2026 Postal Ballot Outcome
Epigral's analyst fair value estimate is maintained at ₹2,000, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, as analysts fine tune their model inputs rather than changing their core view on the stock. What's in the News Epigral has scheduled a Special or Extraordinary Shareholders Meeting on May 19, 2026, to be conducted via postal ballot in India (Key Developments).Actualización de narrativa • Apr 06
EPIGRAL: Steady ₹2,000 View Will Await Q3 Board Outcome
Analysts now keep Epigral's fair value estimate broadly unchanged at about ₹2,000 per share, with only minor tweaks to discount rate, revenue growth, profit margin and future P/E assumptions. This signals a largely steady view on the stock's valuation drivers.Actualización de narrativa • Mar 23
EPIGRAL: Steady ₹2,000 Outlook Will Anticipate Q3 Board Meeting Outcome
Analysts have kept Epigral's fair value estimate steady at ₹2,000, with only minor tweaks to the discount rate, revenue growth, profit margin assumptions and future P/E supporting an unchanged price target. What's in the News A board meeting is scheduled on January 30, 2026 to consider the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report.Actualización de narrativa • Mar 08
EPIGRAL: Steady ₹2,000 Fair Value Will Anticipate Q3 Board Review Outcome
Analysts have kept Epigral’s fair value estimate steady at ₹2,000, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects fine tuning of their models rather than a material change in conviction.Actualización de narrativa • Feb 21
EPIGRAL: Reaffirmed ₹2,000 Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000. A slightly lower assumed future P/E and a marginally higher discount rate together support this unchanged price target.Actualización de narrativa • Feb 07
EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts now see fair value for Epigral at ₹2,000.00 per share, with the unchanged target based on updated assumptions on discount rate, revenue growth, profit margin and future P/E that together reflect a recalibration of their long term earnings and valuation framework. What's in the News A board meeting is scheduled on January 30, 2026 to consider unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report from statutory auditors (company filing).Actualización de narrativa • Jan 24
EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000 after updating their assumptions for discount rate, revenue growth, profit margin and future P/E. These revisions support a recalibrated price target narrative rather than a change in the overall valuation direction.Actualización de narrativa • Jan 09
EPIGRAL: New CFO Appointment Is Expected To Strengthen Future Financial Governance
Analysts have cut their price target on Epigral from ₹2,600 to ₹2,000, citing updated assumptions that combine slightly higher revenue growth and profit margins with a lower future P/E multiple. What's in the News Epigral appointed Mr. Rakesh Agrawal as Chief Financial Officer and Key Managerial Personnel, effective 10 November 2025, following a board decision based on the Nomination and Remuneration Committee's recommendation (Key Developments).Artículo de análisis • Dec 26
Returns On Capital At Epigral (NSE:EPIGRAL) Have Hit The Brakes
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Artículo de análisis • Nov 16
Downgrade: What You Need To Know About The Latest Epigral Limited (NSE:EPIGRAL) Forecasts
Market forces rained on the parade of Epigral Limited ( NSE:EPIGRAL ) shareholders today, when the covering analyst...Artículo de análisis • Nov 13
Epigral Limited Just Missed Earnings - But Analysts Have Updated Their Models
Epigral Limited ( NSE:EPIGRAL ) shareholders are probably feeling a little disappointed, since its shares fell 9.0% to...Artículo de análisis • Nov 11
If EPS Growth Is Important To You, Epigral (NSE:EPIGRAL) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Artículo de análisis • Sep 28
Epigral (NSE:EPIGRAL) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Actualización de narrativa • Aug 06
Capacity Expansion And Green Energy Will Unlock Global Opportunities
The increase in Epigral’s consensus analyst price target to ₹2600 primarily reflects higher anticipated future earnings multiples, as indicated by the rise in future P/E, while the discount rate remains stable. What's in the News Upcoming board meeting to consider un-audited Q1 FY26 results and review fund-raising proposals via debt instruments.Artículo de análisis • Aug 06
Epigral Limited Just Recorded A 98% EPS Beat: Here's What Analysts Are Forecasting Next
NSEI:EPIGRAL 1 Year Share Price vs Fair Value Explore Epigral's Fair Values from the Community and select yours As you...Artículo de análisis • Jul 30
Epigral Limited (NSE:EPIGRAL) Might Not Be As Mispriced As It Looks
With a price-to-earnings (or "P/E") ratio of 23.6x Epigral Limited ( NSE:EPIGRAL ) may be sending bullish signals at...Artículo de análisis • Jun 02
Investors Should Be Encouraged By Epigral's (NSE:EPIGRAL) Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Artículo de análisis • Apr 03
Subdued Growth No Barrier To Epigral Limited (NSE:EPIGRAL) With Shares Advancing 25%
Epigral Limited ( NSE:EPIGRAL ) shareholders would be excited to see that the share price has had a great month...Artículo de análisis • Feb 28
Calculating The Fair Value Of Epigral Limited (NSE:EPIGRAL)
Key Insights Epigral's estimated fair value is ₹1,644 based on 2 Stage Free Cash Flow to Equity With ₹1,630 share...
Nueva narrativa • Jan 16
Doubling CPVC And ECH Production Will Strengthen Future Prospects
Epigral is expanding production capacity and focusing on high-margin value-added products to enhance earnings and future growth.Artículo de análisis • Dec 18
Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Artículo de análisis • Jul 04
Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story
Epigral Limited ( NSE:EPIGRAL ) shareholders would be excited to see that the share price has had a great month...Artículo de análisis • Apr 19
Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump
The Epigral Limited ( NSE:EPIGRAL ) share price has done very well over the last month, posting an excellent gain of...Artículo de análisis • Feb 23
Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward
Despite an already strong run, Epigral Limited ( NSE:EPIGRAL ) shares have been powering on, with a gain of 28% in the...Artículo de análisis • Feb 21
Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...Artículo de análisis • Apr 05
Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Rentabilidad de los accionistas
| EPIGRAL | IN Chemicals | Mercado IN | |
|---|---|---|---|
| 7D | 2.5% | -1.4% | -0.2% |
| 1Y | -39.0% | -1.1% | 2.4% |
Rentabilidad vs. Industria: Los resultados de EPIGRAL fueron inferiores a los de la industria Indian Chemicals, que obtuvo un rendimiento del -1.1% el año pasado.
Rentabilidad vs. Mercado: EPIGRAL obtuvo unos resultados inferiores a los del mercado Indian, que fueron del 2.4% el año pasado.
Volatilidad de los precios
| EPIGRAL volatility | |
|---|---|
| EPIGRAL Average Weekly Movement | 5.9% |
| Chemicals Industry Average Movement | 5.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Precio estable de las acciones: EPIGRAL no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Indian.
Volatilidad a lo largo del tiempo: La volatilidad semanal de EPIGRAL (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2007 | 1,135 | Kaushal Soparkar | www.epigral.com |
Epigral Limited fabrica y vende cloroalcalinos y derivados relacionados en la India y a escala internacional. La empresa ofrece resinas de cloruro de polivinilo clorado (CPVC), epiclorhidrina, cadena de valor de clorometanos, peróxido de hidrógeno, sosa cáustica, cloro, hidrógeno y productos de potasa cáustica. También se dedica al comercio de productos agroquímicos.
Resumen de fundamentos de Epigral Limited
| Estadísticas fundamentales de EPIGRAL | |
|---|---|
| Capitalización bursátil | ₹48.58b |
| Beneficios(TTM) | ₹2.71b |
| Ingresos (TTM) | ₹26.26b |
17.9x
Ratio precio-beneficio (PE)1.8x
Ratio precio-ventas (PS)¿Está EPIGRAL sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de EPIGRAL | |
|---|---|
| Ingresos | ₹26.26b |
| Coste de los ingresos | ₹16.48b |
| Beneficio bruto | ₹9.78b |
| Otros gastos | ₹7.07b |
| Beneficios | ₹2.71b |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 62.82 |
| Margen bruto | 37.24% |
| Margen de beneficio neto | 10.32% |
| Ratio deuda/patrimonio | 25.8% |
¿Cómo se ha desempeñado EPIGRAL a largo plazo?
Ver rendimiento histórico y comparativaDividendos
0.4%
Rentabilidad actual por dividendo6%
Ratio de pagosAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/23 05:46 |
| Precio de las acciones al final del día | 2026/08/21 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Epigral Limited está cubierta por 4 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | BP Wealth Management Private Limited |
| null null | Emkay Global Financial Services Ltd. |
| Meet Vora | Emkay Global Financial Services Ltd. |